Repositioning Candidate Details
| Candidate ID: | R0842 |
| Source ID: | DB05659 |
| Source Type: | investigational |
| Compound Type: | small molecule |
| Compound Name: | Faropenem medoxomil |
| Synonyms: | Faropenem daloxate; Faropenem medoxil; Faropenem medoxomil |
| Molecular Formula: | C17H19NO8S |
| SMILES: | [H][C@]12SC(=C(N1C(=O)[C@]2([H])[C@@H](C)O)C(=O)OCC1=C(C)OC(=O)O1)[C@@]1([H])CCCO1 |
| Structure: |
|
| DrugBank Description: | Faropenem medoxomil is an ester prodrug derivative of the beta-lactam antibiotic . The prodrug form of faropenem offers dramatically improved oral bioavailability and leads to higher systemic concentrations of the drug. Faropenem medoxomil is a broad-spectrum antibiotic that is highly resistant to beta-lactamase degradation. It is being developed jointly by Replidyne, Inc. and Forest Laboratories, Inc. |
| CAS Number: | 141702-36-5 |
| Molecular Weight: | 397.4 |
| DrugBank Indication: | Investigated for use/treatment in bacterial infection, bronchitis, otitis media, and pediatric indications. |
| DrugBank Pharmacology: | Faropenem has demonstrated excellent in vitro activity against common respiratory pathogens, many aerobic gram-positive organisms, and anaerobes. Activity against gram-negative organisms is more reserved. In vivo data suggest that faropenem is efficacious in treating community-acquired infections including uncomplicated skin and skin structure infections; however, more data may help to characterize faropenem's place in antimicrobial therapy. |
| DrugBank MoA: | Like other beta-lactam antibiotics, faropenem acts by inhibiting the synthesis of bacterial cell walls. It inhibits cross-linkage between the linear peptidoglycan polymer chains that make up a major component of the cell wall of Gram-positive bacteria. It does this by binding to and competitively inhibiting the transpeptidase enzyme used by bacteria to cross-link the peptide (D-alanyl-alanine) used in peptidogylcan synthesis. |
| Targets: | Penicillin-binding protein 1A; Penicillin-binding protein 2B; Peptidoglycan synthase FtsI |
| Inclusion Criteria: | Indication associated |
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs |
|---|
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
|---|
| Diseases ID | DO ID | Disease Name | Definition | Class |
|---|